Company profile
South American Gold Corp.
OTC: SAGD · Healthcare · Drug Manufacturers - Specialty & Generic
#1117 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ —GM —SS 30
v0.1 · 5/100 weight · pillars only
↑ revenue growth (YoY), 3-yr revenue growth · ↓ Piotroski F, balance-sheet leverage
Methodology →Revenue TTM
$43.8k
Rev growth YoY (TTM)
-35.2%
Net income (FY)
-$119.1k
Employees
2
as of 2026-08-28
Market cap
$67.7k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$20.0k$20.0k2017
Net income-$119.1k-$119.1k2017
Operating income-$9.5k-$9.5k2017
Total assets$24.6k$24.6k2017
Liabilities$1.6M$1.6M2017
Equity-$1.6M-$1.6M2017
Revenue trend
FY2010 – FY2017 · USD
FY10
FY11
FY12
FY13
FY14
FY15
FY16
FY17
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is South American Gold Corp.’s revenue?
South American Gold Corp. booked $20.0k in FY2017 revenue, growing 144% year over year — faster than most Healthcare companies we track, at a -595.3% net margin.
Peers · Healthcare
Senti Biosciences, Inc.27DJupiter Neurosciences, Inc.18DSkinvisible, Inc.29DTHC Farmaceuticals, Inc.——Sector 10, Inc.——Nanobac Pharmaceuticals, Incorporated——Neighbors
Clark →Key facts
CEODavid Reeves
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersLas Vegas, NV
ExchangeOTC: SAGD
Employees2
IPO date2010-09-27
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.